For US Healthcare Professionals Only

ORDERING BIORPHEN

CONTRACTED SUPPLIER WITH

BIORPHEN IS NOW AVAILABLE

Contact your wholesaler about how to order Biorphen.

Ordering Information

PRODUCT	NDC	Concentration
Biorphen	71863-202-06	500 mcg / 5mL (100mcg/mL) AMP 10X5 ML

WHOLESALER	ITEM NUMBER
AmerisourceBergen	10231623
Cardinal	5579537
McKesson	1528041
Morris & Dickson	887638
Henry Schein	1375835

Please contact your wholesaler representative for Biorphen pricing.

Standardizing biorphen made easy

Have you considered ALL areas of your hospital that could use Biorphen?

Phenylephrine is administered in a variety of hospital environments (eg, OR, ED, ICU, ASC).

Ready-to-use Biorphen does not require compounding or dilution.²

Training is crucial to make sure staff members understand how to use Biorphen and how it differs from your previous method of administering phenylephrine.

Have questions or need more information about Biorphen?

References:

Biorphen data on file. Deer Park, IL: Eton Pharmaceuticals Inc; 2019.
Biorphen [Package Insert]. Deer Park, IL: Eton Pharmaceuticals Inc; 2019.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None

WARNINGS AND PRECAUTIONS

Biorphen can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. Can also cause excessive peripheral and visceral vasoconstriction, and ischemia to vital organs. Extravasation during intravenous administration can cause necrosis or sloughing of tissue. Can cause severe bradycardia and decreased cardiac output, and can increase the need for renal replacement therapy in patients with septic shock, increased pressor effect in patients with autonomic dysfunction, and increased pressor effect with concomitant oxytocic drugs.

Overdose of Biorphen can cause a rapid rise in blood pressure. Symptoms of overdose include headache, vomiting, hypertension, reflex bradycardia, a sensation of fullness in the head, tingling of the extremities, and cardiac arrhythmias including ventricular extrasystoles and ventricular tachycardia.

ADVERSE REACTIONS

Most common adverse reactions during treatment: nausea, vomiting, and headache. To report SUSPECTED ADVERSE REACTIONS, contact Eton Pharmaceuticals at 855-224-0233 or FDA at 1-800-FDA-1088.

DRUG INTERACTIONS

Agonistic Effects (increase in Biorphen blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytoxin, oxytocin, and oxytocic drugs, tricyclic antidepressants, angiotensin, aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids.
Antagonistic Effects (decrease in Biorphen blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines, ACE inhibitors, and centrally acting sympatholytic agents.

For more information, please see
Biorphen Full Prescribing Information.

Indications and Usage

Biorphen® (phenylephrine hydrochloride) is indicated for patients with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

All contents copyright 2022 by Eton Pharmaceuticals, Inc. All rights reserved.
All trademarks are the property of their respective owners.
1102-v1